A Study of Avastin (Bevacizumab) and Transarterial Chemoembolisation (TACE) Treatment in Patients With Liver Cancer
Status:
Completed
Trial end date:
2011-05-01
Target enrollment:
Participant gender:
Summary
This single-arm, open-label study assessed the efficacy and safety of Avastin (bevacizumab)
treatment combined with transarterial chemoembolisation (TACE) in patients with localized
unresectable liver cancer. Patients were treated with TACE at 8 or 10 week intervals for 4
sessions (continuation depended on investigator's discretion). Avastin 5 mg/kg intravenously
was administered 24-48 hours prior to each TACE session and every 2 weeks between the TACE
sessions until disease progression.